PMID- 36123933
OWN - NLM
STAT- MEDLINE
DCOM- 20220922
LR  - 20221108
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 101
IP  - 37
DP  - 2022 Sep 16
TI  - HER2 protein expression correlates with Lauren classification and P53 in gastric 
      cancer patients.
PG  - e30647
LID - 10.1097/MD.0000000000030647 [doi]
LID - e30647
AB  - Human epidermal growth factor receptor 2 (HER2) is a key pathological 
      characteristic of gastric cancer (GC). However, the clinical significance of HER2 
      expression in gastric carcinoma remains controversial. The purpose of this study 
      was to analyze the clinicopathological characteristics of HER2 protein 
      expression, Lauren classification and tumor protein p53 (P53) expression and to 
      evaluate the clinical significance of HER2 protein expression. A total of 176 
      consecutive patients were prospectively recruited between January 2014 and 
      December 2016 at the Second Affiliated Hospital of Zhejiang University School of 
      Medicine. Histological analysis of the resected tissue was performed for HER2 
      protein expression using immunohistochemistry (IHC) and fluorescence in situ 
      hybridization (FISH). Additionally, the expression status of HER2 protein and 
      clinicopathological features were analyzed using the chi-squared (chi2) test. 
      Survival analysis was performed using the Kaplan-Meier method, and differences 
      between the survival curves were determined using the log-rank test. All 
      statistical analyses were conducted using SPSS 22.0 statistical software program 
      (IBM Corp., Armonk, NY). A total of 176 patients with GC were enrolled in this 
      study. Intratumoral heterogeneity of HER2 protein overexpression was observed in 
      42 of 176 cases with IHC grade 2+, accompanied by FISH positivity and IHC grade 
      3+. HER2 protein expression was correlated with tumor differentiation (P < .001), 
      Lauren classification (P = .001), Borrmann type (P = .003) and P53 expression 
      (P < .001). HER2 protein positivity was associated with significantly higher 
      overall survival (OS) (P = .038). Overexpression of HER2 protein was observed in 
      23.9% of the cases and was significantly related to the Lauren intestinal subtype 
      and P53 negative expression. HER2 protein overexpression was independently 
      associated with higher OS.
CI  - Copyright (c) 2022 the Author(s). Published by Wolters Kluwer Health, Inc.
FAU - Chu, Yiming
AU  - Chu Y
AUID- ORCID: 0000-0003-1008-8264
AD  - Department of Gastrointestinal Surgery, The First Affiliated Hospital of Zhejiang 
      Chinese Medicine University, Hangzhou, Zhejiang, China.
AD  - Department of Surgery, The Second Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Li, Hongbo
AU  - Li H
AD  - Department of Surgery, The Second Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Wu, Dan
AU  - Wu D
AD  - Department of Surgery, The Second Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Guo, Qingqu
AU  - Guo Q
AD  - Department of Surgery, The Second Affiliated Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (TP53 protein, human)
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Receptor, ErbB-2/*metabolism
MH  - *Stomach Neoplasms
MH  - Tumor Suppressor Protein p53/*metabolism
PMC - PMC9478214
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2022/09/21 06:00
MHDA- 2022/09/23 06:00
PMCR- 2022/09/16
CRDT- 2022/09/20 01:41
PHST- 2022/09/20 01:41 [entrez]
PHST- 2022/09/21 06:00 [pubmed]
PHST- 2022/09/23 06:00 [medline]
PHST- 2022/09/16 00:00 [pmc-release]
AID - 00005792-202209160-00098 [pii]
AID - 10.1097/MD.0000000000030647 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2022 Sep 16;101(37):e30647. doi: 
      10.1097/MD.0000000000030647.